China's Innovative Drug Sector Sees Sustained Structural Opportunities, Funding Improves
A research report from China Securities (中信建投) indicates that China's innovative drug industry is experiencing sustained structural opportunities and improving investment and financing conditions. The domestic Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors, after an adjustment period from 2022 to 2024, are showing signs of recovery. This recovery is partly driven by a rebound in overseas investment and financing, leading to improved overseas orders for leading Chinese CXO companies in 2024. The report anticipates a continued resurgence in domestic investment and financing starting in the second half of 2025, fueled by large-scale overseas licensing deals for Chinese innovative drug assets. Concurrently, domestic demand within the industry is expected to stabilize and increase. Since the beginning of 2026, the long-term structural opportunities in China's innovative drug sector have been consistently materializing, with ongoing improvements in investment and financing. New drug modality tracks remain highly active and are expanding their output. China Securities believes that the CRO/CDMO industry will see accelerated growth in new contract signings and performance in 2026, ushering in a new phase of development for the entire CXO industrial chain.
The report from China Securities highlights a projected recovery and growth phase for China's innovative drug and CXO sectors, driven by both international and domestic market dynamics. The analysis suggests a cyclical pattern of adjustment followed by resurgence, influenced by global capital flows and domestic policy support. The emphasis on structural opportunities and new drug modalities points to a strategic shift within the industry towards innovation and specialized services. Looking ahead, the interplay between overseas licensing, domestic demand, and R&D investment will be critical in sustaining this growth trajectory. Investors and industry participants will likely monitor the pace of contract signings and revenue growth as key indicators of the sector's health and its ability to navigate evolving global pharmaceutical landscapes and technological advancements in drug discovery and development.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.